ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "Antimalarial drugs and systemic lupus erythematosus (SLE)"

  • Abstract Number: 1590 • ACR/ARHP Annual Meeting 2017

    Prolonged Antimalarial Treatment Increases the Risk for Severe Brady-Arrhythmias in Systemic Lupus Erythematosus

    Konstantinos Tselios1, Dafna D Gladman2, Paula Harvey3, Jiandong Su4 and Murray Urowitz5, 1Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Severe brady-arrhythmias [complete atrioventricular block (cAVB) and sick sinus syndrome (SSS)] have a prevalence of 0.04% and 0.8% in the general population respectively and…
  • Abstract Number: 1592 • ACR/ARHP Annual Meeting 2017

    Antimalarial-Induced Cardiomyopathy in Systemic Lupus Erythematosus

    Konstantinos Tselios1, Mery Deeb2, Dafna D Gladman3, Paula Harvey4, Shadi Akhtari4, Susanna Mak5, Jagdish Butany6 and Murray Urowitz7, 1Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toront, ON, Canada, 3Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 4Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, 5Mecklinger Family and Posluns Family 
Cardiac Catheterization Research Laboratory, University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, 6Department of Pathology and Laboratory Medicine, University Health Network, Toronto, ON, Canada, 7Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Antimalarials (AM) are currently recommended for the management of all patients with systemic lupus erythematosus (SLE) without specific contra-indications. Their main adverse effect is…
  • Abstract Number: 2612 • ACR/ARHP Annual Meeting 2017

    Disparities in Antimalarial Prescribing for Systemic Lupus Erythematosus Using a Real-World, Electronic Health Record

    J.B. Boone, Wendy Xiong, Cecilia P. Chung, Leslie Crofford and April Barnado, Medicine, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Antimalarials (AMs) reduce disease activity and improve survival in patients with systemic lupus erythematosus (SLE) and are recommended regardless of disease severity. Prior studies…
  • Abstract Number: 2617 • ACR/ARHP Annual Meeting 2017

    Electrocardiogram Abnormalities Related to Antimalarials in Systemic Lupus Erythematosus

    Taneisha McGhie1, Paula Harvey2, Jiandong Su1, Nicole Anderson3, George A. Tomlinson4 and Zahi Touma5, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, 3Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Medicine, Mount Sinai Hospital, Toronto, ON, Canada, 5Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada

    Background/Purpose: Anti-malarials (AM), such as hydroxychloroquine (HCQ) and chloroquine (CQ), have long been used for the treatment of systemic lupus erythematosus (SLE). However, despite their…
  • Abstract Number: 754 • ACR/ARHP Annual Meeting 2016

    The Duration of Anti-Malarial Agent Intake in the First 5 Years of the Disease and Prognosis in Patients with Systemic Lupus Erythematosus

    Rattapol Pakchotanon1, Dafna D. Gladman2, Jiandong Su2 and Murray Urowitz3, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 3Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Anti-malarial agents (AM) prevent damage in patients with systemic lupus erythematosus (SLE). We aimed to examine whether the duration of AM therapy early in…
  • Abstract Number: 1793 • ACR/ARHP Annual Meeting 2015

    Is There a Relationship Between Antimalarial Treatment and Elevated Muscle Enzymes in Systemic Lupus Erythematosus

    Konstantinos Tselios1, Dafna Gladman2, Jiandong Su2 and Murray Urowitz2,3, 1Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Elevated muscle enzymes in the course of systemic lupus erythematosus (SLE) usually represent active myositis or drug-related toxicity. Lipid-lowering agents and, less frequently, antimalarials…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology